Cite
HARVARD Citation
How, J. et al. (2022). A nonrandomized phase I and biomarker trial of regorafenib in advanced myeloid malignancies. EJHaem. 3 (2), pp. 434-442. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
How, J. et al. (2022). A nonrandomized phase I and biomarker trial of regorafenib in advanced myeloid malignancies. EJHaem. 3 (2), pp. 434-442. [Online].